We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Surgery for Recurrent Glioblastoma

*Vamsi Krishna Yerramneni, Ramanadha Reddy Kanala,
Vasundhara S. Rangan and Thirumal Yerragunta*

Abstract

Recurrence of glioblastoma (GB) is inevitable. As the optimal management for recurrent glioblastoma continues to evolve, clear treatment guidelines for are lacking. Existing literature does not clarify the role that second surgery plays in the treatment of these patients. Although few studies report that second surgery is beneficial in select patients and leads to longer overall survival (OS), other studies have demonstrated the limited impact that repeat surgery has on the eventual patient outcome. Maximal safe resection (high extent of resection—EOR) has been proven to improve the OS at reoperation, even when undertaken for cases where the first surgery achieved only a limited EOR. Karnofsky Performance Score (KPS) and age at presentation are valuable prognostic factors that predict better OS and aid in better patient selection for surgical management. The true value of reoperation versus systemic treatment, their effects the patient's QoL and the added increase in overall survival is better judged after detailed investigation by means of a prospective, randomized trial.

Keywords: EOR—extent of resection, KPS—Karnofsky Performance Score, rGB—recurrent glioblastoma

1. Introduction

Glioblastoma (GB) is not only the most common primary intrinsic brain tumor of adulthood, but also the most frequently encountered malignant subtype. The standard treatment for newly diagnosed GB remains maximal surgical resection followed by concomitant or adjuvant chemotherapy [1]. The culmination of all the developments in diagnostics, imaging, surgical refinements and adjuvant therapies has not translated into any significant boost to the median overall survival (OS) of these patients. Prognosis continues to be dismal and OS has risen by just about 3.3 months (from 11.3 to 14.6 months) [2]. In select cohorts (consisting of a very favorable subset of patients), a median OS of 20.5 months has been observed. Recurrence is inevitable in GB despite every kind of known therapy. The standard care of the recurrent GB (rGB) is incompletely defined. Considering the ineffectiveness of therapy for first time disease, patients with recurrent disease are left with even more limited truly useful treatment options. With no clear standard of care, available options include reexcision of the lesion, angiogenesis inhibitor agents, and other targeted therapies, some of which have been the subject of clinical trials. In current practice, second surgery is performed in less than one half of the patients

who present with rGB. This might be either due to a seemingly inoperability of the lesion or poor surgical fitness of the patient [3, 4]. Several studies and reviews are published, but undertaking extensive surgery in the recurrence of a disease defined by poor prognosis continues to remain controversial.

2. Criteria for diagnosis of recurrent GB

Criteria for diagnosis have undergone many modifications over past decade. Magnetic resonance imaging every 2–3 months remains the gold standard for assessment of response and progression of the GB. The Macdonald criteria have served as the standard tool in follow up and evaluation of this disease until 2010 and their widespread use has led to the observation of several shortcomings [5, 6]. These include the problem of measuring tumor deposits shaped irregularly (including tumor forming the lining of cystic or excision cavities), observer to observer variability, lack of guidance for the evaluation of multifocal tumors as well as non-enhancing portion(s) of the tumor [5, 6]. Wen et al. published updated criteria in 2010 with restricted parameters for diagnosis of progressive disease within 3 months after completion of adjuvant therapy and integration of the evaluation of T2/FLAIR sequences as well of corticosteroid use [6].

According to the Macdonald et al. [5] criteria, progression of the tumor is defined as development of one or more of the following features:

“25% increase in sum of the products of perpendicular diameters of enhancing lesions, development of any new lesion on imaging and/or clinical deterioration.”

The lack of specificity of enhancement in GB patients treated with surgery, radiation or chemotherapy as well as other difficulties in standardization of assessment by the above criteria led to the need for updated Response Assessment in Neurooncology group (RANO) criteria. These criteria define progression as presence of any one of the following:

“≥25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease) or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy not caused by comorbid events (e.g., radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects); any new lesion; clear clinical deterioration not attributable to other causes apart from the tumor (e.g., seizures, medication adverse effects, complications of therapy, cerebrovascular events, infection, and so on) or changes in corticosteroid dose; failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease.”

Figure 1 is an example of recurrent GBM managed by surgery followed by Bevacizumab chemotherapy.

3. Indications of surgery

Surgery is indicated in patients who show both:

1. Progression of disease according to MacDonald or RANO radiological criteria.

2. Deterioration in clinical status (as manifested by development of new deficits, change in neurological status due to mass effect of the lesion, seizures, or, features of raised intracranial pressure).

The decision to undertake repeat surgery is especially valid in young patients, patients with good functional status and a conveniently resectable tumor.

In rGB, surgery is undertaken with the main aim of cytoreduction. The reduced tumor burden is thought to cause an improvement in OS [7, 8]. Lu et al. in their meta-analysis concluded that repeat surgery has an overall positive role in managing recurrent GBM. It was observed that surgery resulted in a prognostic benefit that was observed to be independent of demographic as well as clinical parameters [8]. Various factors which are found to affect prognosis are age, extent of resection at repeat surgery, adjuvant chemoradiation, tumor location, methylation status, in addition to

Figure 1.
(1a–1d) MRI brain T2 Axial, Axial FLAIR, Axial contrast and sagittal contrast images showing Right ParietoOccipital mass with surrounding edema with corresponding enhancement on the contrast. Surgical excision of the tumor was done with around 60% excision followed by chemoradiotherapy as per Stupp Protocol. (2a–2d) One year after the initial treatment patient follow up MRI (2a–d) shows Tumor regrowth. Patient was taken up for Redo surgical excision and around 70% of the tumor excision was achieved. After second surgery patient was treated in another center with bevacizumab and he came back to us in 3 months with regrowth of the tumor. (3a–3d) Patient had low platelet count as a result of the bevacizumab therapy and was in poor general condition. Surgery excision was not considered as the outcome in patients with poor performance score in recurrent tumor is bad though the MRI does not show an extensive tumor. Poor performance scores with a not so extensive gross tumor on MRI indicate microscopic infiltration.

functional assessment of the patient using scores like Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) score. Nonetheless, studies conducted that have analyzed patient groups after matching for many of these factors have still observed the prognostic advantage conferred by surgery undertaken for recurrent disease. The potential benefit is not limited to the first recurrence only. Superior OS in patients with GB experiencing more repeat surgeries for continuously recurring GB independent of other features has been previously shown [9, 10].

Various factors have been analyzed with respect to surgery in recurrent GB:

3.1 Age

Recent literature proves that age is an important prognostic factor with OS being longer in patients who are younger at the time of diagnosis, in contradiction to older studies which failed to show any meaningful correlation between age and prognosis [9, 11–14]. Although gender has not been commonly thought to be a factor affecting prognosis, a study by Tugcu et al. has interestingly noted that male gender was a factor according better prognosis.

3.2 Timing of second surgery

Studies have shown that survival is not affected by the time interval between initial diagnosis/surgery and repeat surgery [15, 16].

3.3 Performance score

Studies have reported that better performance score at the time of presentation ($KPS \geq 70$) correlates strongly with a longer OS [14, 16–18]. Chang et al. [16, 18, 19] documented that the most important factor affecting OS is KPS at the time of recurrence. Quick et al., on the same lines, have demonstrated that good statistical parallel exists between KPS score and OS in their series [20]. Moreover, Michaelsen et al. have reported that the ECOG Performance Status significantly affects the OS following therapy [13].

3.4 Molecular markers

The role of molecular markers in predicting/affecting survival in recurrent GB has been controversial. Studies have shown an association between loss of MGMT expression and survival in patients with GB. Although this correlation was confirmed to have a prognostic significance at the time of first surgery, Brandes et al. reported that MGMT methylation status has no particular place in the prediction of outcome following repeat surgery. Similarly, multiple authors have noted that MGMT status at the time of redo surgery in GB patients has no effect on OS or on SFR [21, 22]. Mutations of IDH1 and IDH2 are known to be suggestive of secondary GB and to confer favorable prognosis [23, 24]. This was confirmed by Hartmann et al. who reported longer OS in patients with IDH mutant tumors as compared to the IDH wild-type ones. On the contrary, Amelot et al. have reported comparable long term survival in patients with and without IDH1/2 mutation [25, 26].

3.5 Extent of resection

That a greater extent of resection (EOR) confers an obvious advantage in patients being treated for GB has been demonstrated by multiple studies. This has been more widely evaluated and concluded at the time of first surgery [27–32].

It suffices to say that surgical resection of the tumor is still the most effective therapy in GB, leading to instant decompression and improvement in the efficacy of adjuvant radiation by reducing tumor bulk. An increase in survival by an average of 5.5 months was noted by Quick et al. in patients in whom at least 95% of tumor was excised. This benefit was noted irrespective of tumor size. However, it is not as clear if such an advantage is conferred again during operation for recurrence [20]. On inquiry into whether this same benefit holds true in cases of recurrent GB, Robin et al., in their review article found 16 studies reinforcing the role of EOR in patient survival.

According to Stupp et al. surgery (5ALA fluorescence guided complete tumor resection) [35] done at the time of noting disease progression, along with additional chemotherapy (Temozolamide) and radiotherapy improved the average patient survival to more than 14 months. It was thereby suggested that, in patients where surgery for tumor recurrence is deemed prudent, Maximal Safe Resection of the GB should be aimed for [33].

The next logical question that arises would be the role of such ambitious surgery in further recurrences after the second operation. In a series of 578 primary GB patients were studied with reference to the number of repeat surgeries undertaken, Chaichana et al. concluded that patients who underwent multiple resections had better median survival than those who had single time surgery. The 15 patients in this study who underwent resection four times had a median survival of 26.6 months compared to those who were operated once (354 patients), twice (168 patients) and thrice (41 cases). These patients were found to have a median survival of 6.8, 15.5, 22.4 respectively [9].

Bloch et al. also conducted a valuable study on results of multiple resections in 107 patients by four-way subgroup analysis after noting EORs during both first and second surgery. Whether the initial as well as subsequent surgery achieved Gross Total Resection (GTR) or Sub Total Resection (STR) of the tumor was made note of. Patients were then categorized into four resection groups: GTR/GTR, GTR/STR, STR/GTR, and, STR/STR. On follow up, the study established that a survival advantage was conferred by performing complete tumor resection during both initial surgery as well as second surgery for recurrence of GB [31].

A series by Oppenlander and colleagues also confirms the advantage conferred by increased EOR in patients operated for rGB. A survival advantage was observed with even 80% resection of tumor volume. The OS for the entire cohort studied was 19.0 months while median survival on Kaplan-Meier curves showed survival upto 20 months and even 30 months when EOR was greater than 81 and 97%, respectively. Multivariate analysis identified EOR, age, and KPS as independent predictors of survival [30].

Of particular interest is a study by Sanai et al. where in cases when a more complete resection was deemed imprudent due to the tumor being located in eloquent brain, more limited resection (78% EOR) of the contrast enhancing lesion did correspond to a survival benefit that was of significance statistically [4]. Despite being largely based on class II to III evidence, surgically reducing the amount of residual tumor does translate to longer PFS and better OS.

4. Survival following reoperation for recurrent or progressive glioblastoma

With the advancement of refinement in surgical techniques and in nonsurgical adjunctive therapies, our understanding of the impact of surgery on survival in both newly diagnosed and recurrent GB increases. As elaborated so far, varied

studies have come to the common conclusion that a survival benefit is accorded by surgery, especially by the maximization of EOR, not only in newly diagnosed GB, but also in recurrent cases [9, 11, 16, 20, 34].

A detailed review of relevant literature by Ryken et al. suggests that reoperation adds about 8 or 9 months to the OS in select patients, without the added burden of significant morbidity. This positive outcome is especially observed in patients with age less than or equal to 50, KPS scores equal to or greater than 60 or 70 as well as favorable tumor location [36].

It can now be safely said that the most effective therapy in recurrent GB is surgical resection as it improves the efficacy of radiotherapy. Patient selection should take into consideration the so far observed positive prognostic factors and maximal safe tumor volume resection should be the surgical goal [33] in those patients who are candidates to second surgery.

5. Complications

Although surgery logically aims at maximal cytoreduction, the safety of this goal is compromised by factors such as highly infiltrative nature of tumor, eloquent, deep seated/periventricular location, advanced age and/or coexistence of comorbidities. A multicenter retrospective study documented a 2–4% increase in the rate of neurological and non-neurological complications in repeat surgery when compared with initial surgery [37].

Following surgery for rGB, mortality rate has been shown to lie in the range of 0–11% with morbidity rate varying from 13 to 69%, leaving a significant number of rGB patients in a condition that precludes administration of adjuvant therapy [19]. This risk, therefore, appeared to nullify the survival benefit of reoperation at recurrence when compared with patients of recurrence who received no treatment at all. Hence, the importance of safer surgery avoiding morbidity as well as judiciousness in decision making cannot be overstated.

6. Conclusions

The available literature suggests a higher OS in selected patients who were managed with repeat excision of tumor at the time of recurrence of Glioblastoma. Although a debate remains open regarding the benefit of such excision, a clear trend in its favor has become more evident. The decision of undertaking surgery for rGB should be individualized and should surely be considered in patients with a favorable functional score at the time of presentation with recurrent disease as well as favorable preoperative neurological and radiological characteristics. The goal of such repeat surgery should be the resolution of symptoms, stabilization or improvement in QoL, increase in the time to further progression and reduction in requirement of steroid therapy. There is also the additional advantage of the possibility to offer intracavitary adjunctive therapy as well as an improved response to other adjunctive therapies [36]. As is customary to state, the actual value of such repeat surgery in comparison with systemic treatments and the effect of each on patient QoL and survival remains a topic for further prospective, randomized trials.

IntechOpen

IntechOpen

Author details

Vamsi Krishna Yerramneni*, Ramanadha Reddy Kanala, Vasundhara S. Rangan
and Thirumal Yerragunta
Department of Neurosurgery, Nizam's Institute of Medical Sciences, Hyderabad,
India

*Address all correspondence to: vamsiky.ns@gmail.com

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Central Brain Tumor Registry of the United States. Central Brain Tumor Registry of the United States Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2010
- [2] Despite advances in diagnostic technology, surgical techniques and adjuvant treatments, the prognosis remains poor and the median overall survival (OS) of patients has increased only 3.3 months (from 11.3 months to 14.6 months) over the past 25 years
- [3] Robin AM, Lee I, Kalkanis SN. Reoperation for recurrent glioblastoma multiforme. *Neurosurgery Clinics*. 2017;**28**(3):407-428
- [4] Sanai N, Polley M-Y, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. *Journal of Neurosurgery*. 2011;**115**(1):3
- [5] Macdonald D, Cascino T, Schold SJ, et al. Response criteria for phase II studies of supratentorial malignant glioma. *Journal of Clinical Oncology*. 1990;**8**:1277-1280
- [6] Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. *Journal of Clinical Oncology*. 2010;**28**(11):1963-1972
- [7] Vogelbaum MA. The benefit of surgical resection in recurrent glioblastoma. *Neuro-Oncology*. 2016;**18**:462-463
- [8] Lu VM, Jue TR, McDonald KL, Rovin RA. The survival effect of repeat surgery at glioblastoma recurrence and its trend: A systematic review and meta-analysis. *World Neurosurgery*. 2018;**115**:453-459
- [9] Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, et al. Multiple resections for patients with glioblastoma: Prolonging survival. *Journal of Neurosurgery*. 2013;**118**(4):812-820
- [10] Chen YR, Sole J, Ugiliweneza B, Johnson E, Burton E, Woo SY, et al. National trends for reoperation in older patients with glioblastoma. *World Neurosurgery*. 2018;**113**:179-189
- [11] Sughrue ME, Sheean T, Bonney PA, Maurer AJ, Teo C. Aggressive repeat surgery for focally recurrent primary glioblastoma: Outcomes and theoretical framework. *Neurosurgical Focus*. 2015;**38**(3):E11
- [12] Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, et al. The effect of re-operation on survival in patients with recurrent glioblastoma. *Anticancer Research*. 2015;**35**(3):1743-1748
- [13] Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: An observational study of a cohort of consecutive non-selected patients from a single institution. *BMC Cancer*. 2013;**3**(13):402
- [14] Stark AM, Hedderich J, Held-Feindt J, Mehdorn HM. Glioblastoma—The consequences of advanced patient age on treatment and survival. *Neurosurgical Review*. 2007;**30**(1):56-61
- [15] Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D,

- et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. *Neuro-Oncology*. 2008;**10**(1):79-87
- [16] Park JK, Hodges T, Arko L, Shen M, DelloIacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. *Journal of Clinical Oncology*. 2010;**28**(24):3838-3843
- [17] Tugcu B, Postalci LS, Gunaldi O, Tanriverdi O, Akdemir H. Efficacy of clinical prognostic factors on survival in patients with glioblastoma. *Turkish Neurosurgery*. 2010;**20**(2):117-125
- [18] Hervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: A current perspective of the literature. *Neurosurgery*. 2014;**75**(5):491-499
- [19] De Bonis P, Fiorentino A, Anile C, Balducci M, Pompucci A, Chiesa S, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. *Clinical Neurology and Neurosurgery*. 2013;**115**(7):883-886
- [20] Quick J, Gessler F, Dützmänn S, Hattingen E, Harter PN, Weise LM, et al. Benefit of tumor resection for recurrent glioblastoma. *Journal of Neuro-Oncology*. 2014;**117**(2):365-372
- [21] Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: Clinical implications. *Neuro-Oncology*. 2010;**12**(3):283-288
- [22] Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). *British Journal of Cancer*. 2006;**95**(9):1155-1160
- [23] Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, et al. Personalized care in neuro-oncology coming of age: Why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. *Neuro-Oncology*. 2012;**14**(Suppl. 4):iv100-iv108
- [24] Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? *Nature Reviews. Neurology*. 2010;**6**(1):39-51
- [25] Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al. Germanglioma network long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. *Clinical Cancer Research*. 2013;**19**(18):5146-5157
- [26] Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, et al. IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. *PLoS One*. 2015;**10**(7):e0130596
- [27] Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. *Journal of Neurosurgery*. 2001;**95**(2):190-198
- [28] Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. *Neuro-Oncology*. 2014;**16**(1):113-122
- [29] Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: Limiting factors,

perception of resectability, and effect on survival. *Journal of Neurosurgery*. 2012;**117**(5):851-859

[30] Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *Journal of Neurosurgery*. 2014;**120**(4):846-853

[31] Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. *Journal of Neurosurgery*. 2012;**117**(6):1032-1038

[32] McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. *Journal of Neurosurgery*. 2009;**110**(1):156-162

[33] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *The New England Journal of Medicine*. 2005;**352**(10):987-996

[34] Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *The Lancet Oncology*. 2008;**9**(1):29-38

[35] Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. ALA-Glioma study group: Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. *Neurosurgery*. 2008;**62**(3):564-576

[36] Ryken TC, Kalkanis SN, Buatti JM, Olson JJ, AANS/CNS Joint Guidelines Committee. The role of cytoreductive surgery in the management of progressive glioblastoma: A systematic

review and evidence-based clinical practice guideline. *Journal of Neuro-Oncology*. 2014;**118**(3):479-488

[37] Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. *Neuro-Oncology*. 2016;**18**(1):96-104